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Abstract
Purpose The anion channel protein band 3 is the main
target of the pathogenic red blood cells (RBC) autoanti-
bodies in New Zealand black (NZB) mice. CD4 T cells
from NZB mice with autoimmune hemolytic anemia
respond to band 3. Previously, we have shown that IL-10
and peptides containing a dominant T cell epitope from red
cell band 3 modulate autoimmune hemolytic anemia in
NZB mice. Because of the immunoregulatory role of IL-10
in autoimmune diseases, we aim to identify individual band
3 peptides that induce high IL-10 production and simulta-
neously suppress CD4 T cell proliferation and to investi-
gate the effect intranasal administration of IL-10 producing
band 3 peptides on autoantibody responses of NZB mice.
Methods Splenic CD4 T cells of NZB mice were isolated
and stimulated by co-culture of T cells with individual
band 3 peptides. IL-10 production was measured by
enzyme-linked immunosorbent assay and proliferative
response of CD4 T cells was estimated by incorporation of
[3H] thymidine assay. NZB mice were given either PBS, or
peptides 25 (241–251) and 29 (282–296) or both peptides
intranasally on three occasions at 2-day intervals. The mice
were bled at 6, 10 and 18 weeks after peptide inhalation,
and the number of RBC auto-antibodies was measured by
DELAT and hematocrit values were assessed.
Results Peptides 25 (241–251) and 29 (282–296) induced
the highest IL-10 production by CD4 T cells. These pep-
tides also inhibited the peak T cell proliferative response. 6
and 10 weeks after peptide inhalation, the total IgG, IgG1
and IgG2a in mice treated with both peptides 241–251 and
282–296 were significantly higher than control (P\ 0.05).
However, no significant difference in the mean hematocrit
between of the peptide-treated mice and the control group
was found.
Conclusions Although band 3 peptides 241–251 and
282–296 induced to the highest IL-10 production by CD4 T
cells in vitro but fail to reverse the RBC autoantibody
response in vivo. Modifications to improve solubility these
peptides might help to modulate the immune response
toward a T helper-2 profile and decrease the severity of
anemia.
Keywords Autoimmune hemolytic anemia  IL-10  CD4
T cells  Band 3 peptides
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Introduction
There is a pressing need to develop specific immunother-
apies for autoimmune diseases, and considerable attention
is focused on the potential beneficial effects of peptides
recognized by auto-reactive CD4 T cells. However, before
such treatments can become a reality for human disease, it
is important to understand the mechanisms underlying the
action of these peptides, particularly in antibody-mediated
conditions, where their effects are less well understood.
Spontaneous autoimmune hemolytic anemia (AIHA) in the
New Zealand Black (NZB) mice is a classic example of
autoimmune antibody-mediated disease. NZB mice pro-
duce red blood cell (RBC)-bound IgG autoantibodies from
as early as 6 weeks of age [1, 2] and develop signs of
anemia some 5 months later [3]. The major target of the
pathogenic RBC autoantibodies is the anion channel pro-
tein band 3 [4], and CD4 T cells from NZB mice respond to
band 3 [1]. The optimal generation of these autoantibodies
is CD4 T cell-dependent since production of the autoanti-
body is retarded in NZB mice treated with anti-CD4 anti-
bodies [5] and in CD4-deficient mice [6]. More recently, it
has been demonstrated that band 3 peptide 861–874 is the
predominant sequence recognized by NZB T cells in vitro
[7]. Mapping studies revealed that the peptide invariably
induces strong proliferation of NZB CD4 T cells in vitro,
and is the only sequence to stimulate responses by T cells
from NZB mice prior to the onset of disease [8]. In addi-
tion, NZB mice given this (relatively insoluble) peptide
develop a more severe disease. By contrast, the severity of
anemia is reduced in NZB mice given a soluble analog of
the peptide [9], showing that this disease is susceptible to
peptide therapy.
IL-10 is anti-inflammatory cytokine with potent prop-
erties that maintains normal tissue homeostasis. Impair-
ment of IL-10 is associated with high risk for development
of many autoimmune diseases [10]. On the other hand,
injecting NZB mice with plasmids encoding IL-10 (pIL-
10) delayed the development of anemia [11]. Regulatory T
cells control the activity of self-reactive cells in their
lymphoid organs [12]. Previous studies have shown that
IL-10 producing regulatory T cells were able to prevent or
suppress autoimmune diseases. Myelin basic protein
(MBP) peptide 1–9 was recognized by auto-reactive CD4 T
cells and prevented the induction of an autoimmune dis-
ease. Intranasal administration of this peptide prevents the
induction of experimental autoimmune encephalomyelitis
(EAE) in mice by induction of regulatory T cells which
produced IL-10 [13, 14]. In addition, IL-10-producing B
cells (regulatory B10 cells) attenuate autoimmune,
inflammatory reactions, through IL-10 production [15] and
the administration of IL-10 can suppress collagen-induced
arthritis [16], as well as the diabetes of non-obese diabetic
(NOD) mice [17].
In human autoimmune hemolytic anemia, the Rhesus
(Rh) complex carries autoreactive helper determinants
since Rhesus peptide-specific T cells that have been acti-
vated in vivo, can be detected in the peripheral blood of all
patients with anti-Rh autoantibodies [18]. Epitope mapping
studies in AIHA patients identified peptides from the
sequence of the RhD protein that induced IL-10 and sup-
pressed T cell proliferation, and this inhibition was medi-
ated by IL-10 [19]. Thus, the aim of the current work was
to investigate the role of band 3 peptides in the induction of
IL-10 and the suppression of T cell proliferation in the
NZB mice model and to determine whether intranasal
administration of the IL-10 producing band 3 peptides to
NZB mice would modulate the response of the corre-
sponding T cells and RBC autoantibody production and
ameliorate NZB AIHA.
Materials and methods
Mice
NZB (H-2d) mice were maintained under specific patho-
gen-free conditions in the animal facilities at the University
of Bristol. All animal experiments complied with UK
Home office regulations, and the ‘Principles of laboratory
animal care’ were followed throughout.
Peptides
Band 3 peptides [20] were synthesized in the Department
of Biochemistry, University of Bristol, UK by a solid-phase
synthetic method using fluorenylmethoxycarbonyl-poly-
amide chemistry [21]. Individual band 3 peptides were
suspended in phosphate buffered saline (PBS) containing
5% dimethyl sulphoxide (DMSO; Sigma) at 2 mg/ml.
Administration of peptides
Groups of 6-week-old NZB mice were given 25 lL of band
3 peptides 25 (241–251) and 29 (282–296) or both in PBS
(4 mg/mL) intranasally on three occasions (300 lg in total)
at 2-day intervals. The control group received PBS.
Stimulation of T cell
Spleens were harvested from mice and purified CD4 T cells
([95% CD4 as determined by flow cytometry analysis)
were obtained by positive selection using magnetic beads
coated with anti-CD4 mAb (Miltenyi Biotec, Bergisch
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Gladbach, Germany) according to the manufacturer’s
instructions.
The CD4 cells were resuspended in alpha modification
of Eagle’s medium supplemented with 20 mM HEPES
buffer, 100 U/ml benzyl penicillin, 100 lg/ml strepto-
mycin sulfate, 4 mM L-glutamine and 50 lM 2-mercap-
toethanol. Antigen-presenting cells (APCs) were produced
by irradiation of the non-CD4? cells with 1500 rads
(caesium source) to prevent cell division. APCs were
mixed with CD4? cells to reach a final concentration of
0.6 9 106 cells/ml for APCs and 1.25 9 106 cells/ml for
CD4? cells. 1% mouse serum was added as a protein
source. Band 3 peptides were added at a final concentration
of 20 or 200 lg/ml and the cells were incubated in a
humidified atmosphere of 5% CO2 and 95% air at 37 C.
Dominant band 3 peptide 861–874 and its soluble analog as
well as concanavalin A (ConA) were used as positive
controls.
Cell proliferation assay
Cellular proliferation was estimated by incorporation of
[3H] thymidine. Cell proliferation was measured over four
days from day 3 to day 6 of culture. 100 ll samples of each
CD4 T cell culture were added in triplicate to a 96-well
plate and incubated for 6 h with 1 lCi per well of [3H]
thymidine. The cells were incubated in a humidified
atmosphere of 5% CO2 and 95% air at 37 C for 6 h. Cells
were harvested on filter paper, and incorporation of tritiated
thymidine was measured using a 1450 Microbeta Plus
scintillation counter (LKB Wallac, Turku, Finland) in the
department of Cellular and Molecular Medicine, Bristol
University, UK.
ELISA
Production of IL-10 was assessed on day 4/5 of cell culture
by CelELISA for mouse IL-10 (Biosource International,
Nivelles, Belgium) as described previously [20]. Briefly,
cell samples, set up in triplicate, were cultured overnight in
a plate coated with rat anti-mouse IL-10 at 37 C in a
humidified atmosphere of 5% CO2. Post incubation, IL-10
was detected with biotinylated rat anti-mouse IL-10. The
optical densities of plate wells were measured at wave-
length 450 nm and IL-10 levels were calculated by
regression analysis against standard curves produced with
the appropriate recombinant cytokine.
Measurement of IgG subclasses bound to RBC
The levels of IgG molecules bound to the surface of RBC
were measured by direct enzyme-linked anti-globulin test
(DELAT). Briefly, a 2% suspension of fixed RBC were
incubated with subclass-specific sheep anti-mouse IgG
antibody (The Binding Site, Birmingham, United King-
dom) for 1 h at 37 C. After, the RBC were incubated with
alkaline phosphatase–conjugated donkey antisheep anti-
body (Sigma) then washed and allowed to react with
phosphatase substrate solution (p-nitrophenyl phosphate;
Sigma) for 1 h at 37 C. The optical density (OD) mea-
sured at 405 nm (Titertek Multiscan II; Labsystems, Hants,
United Kingdom). The number of molecules of each
murine IgG subclass bound to the RBC was calculated by
interpolation from a standard curve generated by tanning
normal RBC with a known concentration of each purified
IgG subclass (Sigma).
Results
CD4 T cells production of IL-10 by after stimulation
by band 3 peptides
We first examined the IL-10 production by CD4 T cells
in the presence of the individual 92 peptides at two
concentrations 20 lg/ml and 200 lg/ml. Generally,
peptides were able to stimulate higher IL-10 production
at a concentration of 200 lg/ml than at 20 lg/ml. At the
concentration of 20 lg/ml, (Fig. 1) only four peptides (3,
18, 22, 25) were able to stimulate the highest IL-10
production. However, when the different 92 peptides
were used at concentration of 200 lg/ml (Fig. 2) four-
teen peptides at the tested dose were able to stimulate
higher IL-10 production. These peptides include peptides
4, 21, 22, 23, 25, 29, 35, 42, 50, 63, 68, 84, 88 and 89.
The sequence and positions of these peptides are shown
in Table 1 [22].
Effect of IL-10 producing peptides on CD4 T cell
proliferation
Since IL-10 is considered to be a regulatory cytokine, the
ability of these peptides to suppress the proliferative
response of CD4 T cell was examined parallel to the IL-10
production. The proliferative response is expressed as a
stimulation index (SI) which is calculated by dividing the
mean counts per minute (cpm) of peptide-stimulated wells
by the mean cpm of non-stimulated wells. As can be seen
in Fig. 3, peptides 25 (241–251) and 29 (282–296) induced
the highest IL-10 production by CD4 T cells and inhibited
T cell proliferation (SI less than 2.5) compared to the
proliferative response of dominant band 3 peptide 861–874
and its soluble analog with a stimulation index more than
12.
Autoimmun Highlights (2017) 8:7 Page 3 of 9 7
123
Effect of mucosal administration of band 3 peptides
241–251 and 282–296, on NZB mice autoantibody
responses
An experiment was set up to determine if peptide
inhalation affected the level of each IgG isotype of the
RBC-bound autoantibodies. Groups of NZB mice that
had inhaled PBS, band 3 peptides 25 (241–251) and 29
(282–296) or both peptides (pMix). The mice were bled
at 6 and 10 weeks after inhalation, and the number of
antibody molecules of each isotype present on their RBC
was measured by DELAT. When autoantibody responses
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Fig. 1 Production of IL-10 by CD4 T cells after band 3 peptide
stimulation at a dose of 20 lg/ml. Production of IL-10 was assessed
on day 4/5 of cell culture by CelELISA. The X axis represents the
individual 92 peptides of band 3, while the Y axis shows the IL-10
concentration. IL-10 value without peptide was deducted from the test
value. The data shown are means of duplicate samples representative
of three independent experiments
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was analyzed after 6 weeks (Fig. 4) and 10 weeks
(Fig. 5) following peptide inhalation, the total IgG was
significantly higher in p25 and p25 ? p29 groups
(P\ 0.05) and both IgG1 and IgG2a were significantly
higher in p25 ? p29 group (P\ 0.05) compared to
control (One-way ANOVA).
Effect of mucosal administration of band 3 peptides
241–251 and 282–296 on NZB anemia
To test if mucosal administration of band 3 peptides
241–251 and 282–296 affect the rate of hemolysis, groups
of NZB mice were given peptides or PBS intranasally and
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Fig. 2 Production of IL-10 by CD4 T cells induced by 92 peptides of
band 3 at a dose of 200 lg/ml. Production of IL-10 was assessed on
day 4/5 of cell culture by CelELISA. The X axis represents the
individual 92 peptides of band 3, while the Y axis shows the IL-10
concentration. IL-10 value without peptide was deducted from the test
value. The data shown are means of duplicate samples representative
of three independent experiments
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the development of anemia was compared. As can be seen
in Fig. 6, after 6, 10 and 18 weeks of treatment, no sig-
nificant difference in the mean hematocrit between of the
peptide-treated mice and the control group (P[ 0.05)
(One-way ANOVA).
Discussion
NZB mouse model has been used extensively for the
analysis of spontaneous AIHA [1, 2]. In this study we
mapped band 3 peptides that are able to produce IL-10 and
we further investigated the effect of selected IL-10-pro-
ducing peptides on CD4 T cell proliferation. We found that
peptides 25 (241–251) and 29 (282–296) induced the most
IL-10 and suppressed the peak proliferative response of
dominant band 3 peptide 861–874 and its soluble analog.
These data suggest that peptides 25 (241–251) and 29
(282–296) have the potential to be tested as a therapeutic
reagent for AIHA studies.
A number of studies have shown that peptide therapy
induced IL-10-dependent immunological tolerance. In
NOD mice, peptide from heat-shock protein, p277, arrested
beta-cell destruction, maintained insulin production [23]
and induced Th2 cytokines (IL-4 and IL-10) [24]. In
human, cat allergen peptide therapy showed decreased Th1
and Th2 with increased IL-10 [25] and grass pollen
immunotherapy resulted in higher IL-10 production com-
pared to atopic control subjects [26]. Peptides derived from
the antigens associated with allergy and autoimmune dis-
ease may be used as vaccines to treat these disorders [27].
In addition, administration of the plasmids encoding IL-10
(pIL-10) delayed the development of anemia in NZB mice
Table 1 The sequences and positions of selected peptides of band 3
proteins
Peptide no. Amino acid sequence Position
4 YRDLTIPVTEMQDPE 41–55
13 SLLELQKVFSKGTFL 120–134
18 LLLKRSHAEDLGNLE 171–185
22 ETQLYCGQAEGGSEG 210–224
25 LVLVGRANFLEKPVL 241–251
29 LGPEAPHVDYTQLGR 282–296
34 SLVLPPTDAPSEKAL 331–345
35 PSEKALLNLVPVQKE 340–354
42 PYYLSDITDALSPQV 410–424
50 EEAFFSFCESNNLEY 491–505
63 RVIGDFGVPISILIM 621–635
68. LGLYRLFPTWMMFASV 671–686
88 STPASLA LPFVLILT 870–884
89 VLILTVPLRRLILPLIFR 880–897
Dominant peptide CLAVLWVVKSTPAS 861–874
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Fig. 3 IL-10 production and CD4 T cell proliferation elicited by
selected band 3 peptides. The peptides were selected according to
their ability to induce IL-10 production. CD4 T cell were stimulated
with selected peptides at a dose of 200 lg/ml and IL-10 production
was calculated by CelELISA (a) and stimulation index of prolifer-
ative response was measured by incorporation of [3H] thymidine (b).
T cell proliferation as assessed from day 3 to day 6 after co-culture
with peptides. The proliferative response is expressed as a stimulation
index (SI) calculated by dividing the mean cpm of peptide-stimulated
wells by the mean cpm of non-stimulated wells. The data shown are
means of duplicate samples representative of three independent
experiments
7 Page 6 of 9 Autoimmun Highlights (2017) 8:7
123
as judged by increased haematocrit values compared with
controls [11].
How might IL-10-producing peptide influence tolerance
in NZB model? IL-10 may play a role in both the induction
of regulatory cells and their effector function. IL-10
induced differentiation of CD4 T cells into type 1 regula-
tory T (Tr1) cells and prevented colitis induced in severe
combined immunodeficient (SCID) mice by pathogenic
CD4 ? CD45RB (high) splenic T cells. [28]. Additionally,
transfer of Tr1 T cell clones inhibited Ag-specific serum
IgE responses through IL-10 secretion in immediate
hypersensitivity murine model [29]. Moreover, the MBP
peptide 1–9 induced regulatory T cells of the Tr1 type
in vivo, and neutralization of IL-10 prevented the peptide
MBP from protecting against experimental autoimmune
encephalomyelitis [14]. Furthermore, IL-10 was shown to
be essential for the protection of C57BL/6 mice from
experimental autoimmune encephalomyelitis after admin-
istration of the soluble peptide 35–55 from myelin oligo-
dendrocyte glycoprotein [30].
It follows that, at least in some systems; peptides rec-
ognized by auto-reactive CD4 T cells exert their thera-
peutic effect by an IL-10-dependent mechanism. Such
studies, together with the fact that administration of IL-10
can suppress collagen-induced arthritis [16], the diabetes of
NOD [17] mice as well as experimental autoimmune
encephalomyelitis [31], support the potential therapeutic
Fig. 4 RBC autoantibody responses 6 weeks after peptide inhalation.
Comparison of total IgG (a), IgG1 (b) and IgG2a (c) responses of
individual NZB mice 6 weeks after they had inhaled PBS or peptide
25 (241–251) or peptide 29 (282–296) or both (p25 ? p29). Total IgG
was significantly higher in p25 and p25 ? p29 groups (P\ 0.05) and
both IgG1 and IgG2a were significantly higher in p25 ? p29 group in
comparison to control (P\ 0.05) (One-way ANOVA)
Fig. 5 Total IgG, IgG1 and IgG2a 10 weeks after peptide inhalation
10 weeks after peptide inhalation. Comparison of total IgG (a), IgG1
(b) and IgG2a (c) responses of individual NZB mice 10 weeks after
they had inhaled PBS (n = 7) or p25 or p29 or p25 ? p29. Total IgG
was significantly higher in p25 (P\ 0.05) and p25 ? p29 (P\ 0.01)
groups and both IgG1 and IgG2a were significantly higher in
p25 ? p29 group in comparison to control (P\ 0.01) (One-way
ANOVA)
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use of band 3 peptides 241–251 and 282–296 in autoim-
mune hemolytic anemia.
It is known that Th1 cytokine interferon-gamma and
Th2 cytokine IL-4 stimulate isotype switching to IgG2a
and IgG1, respectively [32, 33]. Autoantibody subclasses
IgG2a and IgG1 immunoglobulin isotypes were investi-
gated as indicative of a Th1 and Th2 type responses,
respectively [34].
Previously we have demonstrated that development of
RBC autoantibodies in NZB mice is associated with Thl
cytokine-dominated responses [2]. In vivo experiments
were planned to examine the effect of inhaling the band 3
peptides that induced IL-10 on NZB anemia. It was
expected this treatment would deviate the immune
response toward Th2 cytokines and reduce hemolysis.
However in this study we demonstrated a significant
enhancement of both Th1 and Th2-related IgG subclasses
in response to inhaled peptides and no improvement in
anemia after 18 weeks of treatment. Our findings are
consistent with other studies that have described enhance-
ment of both Th1 and Th2 in response to subcutaneous
immunization of ovalbumin dissolved in saline containing
Chitosan nanoparticles in mice [35] and to inhaled allergic
in atopic children [36]. The results of in our in vivo
experiment may be due to the fact that in NZB disease T
cells primed to inhaled peptides were already generated by
the time therapy was initiated and is likely to reflect the
expansion of CD45RO memory cells [37]. In addition,
solubility of peptides can be a determining factor as
insolubility is often associated with immunogenicity rather
than tolerogenicity. This was clear when inhalation of the
insoluble peptide 861–874 primed T cells for both peptide
861–874 and band 3 responses whereas inhalation of a
soluble analog (Glu861, Lys875) of peptide 861–874
deviated the autoimmune response toward a Th2 profile
[9].
In conclusion, peptides 241–251 and 282–296 stimu-
lated the highest IL-10 production by CD4 T cells and
inhibited the peak T cell proliferative response but failed to
induce tolerance in vivo and accelerated the priming of
band 3-reactive T cells. Designing a soluble analog of band
3 peptides 241–251 and 282–296 should be considered
before intranasal immunization.
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Fig. 6 Comparison of hematocrit values of individual NZB mice.
The mice had inhaled or peptide 25 (241–251) or peptide 29
(282–296) or both (p25 ? p29) and hematocrit values were measured
after 6 weeks (a) 10 weeks (b) and 18 weeks (c). No significant
difference between the groups (P[ 0.05) (One-way ANOVA) was
found at any time point
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